Is Milestone Pharmaceuticals, Inc. overvalued or undervalued?

As of 13 May 2024, the valuation grade for Milestone Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, reflected by its negative Price to Book Value of -15.11 and EV to EBITDA of -1.76. Additionally, the ROE is negative due to a lack of positive book value, further emphasizing the company's financial struggles. In comparison to its peers, Milestone's EV to EBIT ratio of -1.74 stands out against Eton Pharmaceuticals, Inc. with a ratio of -92.8956, and Abeona Therapeutics, Inc. at -4.5154, both of which are also classified as risky. The stark negative ratios across the board suggest that the company is not generating value relative to its peers. Despite a recent uptick in stock price, Milestone's year-to-date return of -25.42% compared to the S&P 500's 2.44% reinforces the notion that it is not a favorable investment at this time.